A prospective, multicentre, observational, postmarketing surveillance study of safety and efficacy of pegteograstim prophylaxis in patients with lymphoma and solid malignancies
Latest Information Update: 29 Oct 2021
Price :
$35 *
At a glance
- Drugs Pegfilgrastim (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
- Indications Breast cancer; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 29 Oct 2021 New trial record
- 01 Sep 2021 Results published in the Supportive Care in Cancer